综合遗传与自身抗体检测提高原发性卵巢功能不全的诊断精确性
前瞻性横断面研究纳入100例新诊断不明原因的原发性卵巢功能不全(POI)女性,在标准筛查基础上增加全外显子测序(含103个卵巢相关基因靶向分析)和类固醇细胞抗原自身抗体检测,将潜在病因诊断率从11%提高到41%。
要点
- 在标准染色体和FMR1前突变筛查基础上,增加全外显子测序和自身抗体检测使POI病因诊断率从11%升至41%。
- 检出染色体异常8%、FMR1前突变3%、POI相关遗传变异16%、自身免疫性POI 3%。
- ZSWIM7基因纯合致病性变异见于两名女性,支持其为单基因POI的新病因。
核心结论
- 在推荐诊断检查基础上增加下一代测序技术(含POI相关基因panel、扩展全外显子测序数据)及特异性自身抗体检测,可将POI潜在病因诊断率从11%提高到41%。
研究设计与样本
- 前瞻性横断面研究,纳入2019年1月至2021年12月连续转诊至挪威卑尔根Haukeland大学医院的100例新诊断不明原因POI女性。
主要发现
- 检出染色体异常8%、FMR1前突变3%、POI相关遗传变异16%、自身免疫性POI 3%。
- 在11%中识别出POI相关的意义未明遗传变异(VUS)。
- 两名女性发现ZSWIM7基因(NM_001042697.2)纯合致病性变异,证实其为单基因POI的新病因。
- 未发现表型与基因型之间的关联。
关键数值与推荐
- 标准推荐诊断检查包括染色体异常筛查和脆性X智力障碍1基因(FMR1)前突变筛查。
- 扩展检测包括全外显子测序(含103个卵巢相关基因靶向分析)和抗类固醇细胞抗原自身抗体检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 使用候选遗传和自身免疫标志物限制了发现新标志物的可能性。
- 为进一步研究遗传变异,家系研究本会有帮助。
- 在来自非洲的女性中发现遗传变异比例相对较高,而基因组数据库缺乏遗传多样性可能影响诊断准确性。
- 由于没有特定临床或生化标志物预测POI的潜在病因,关于哪些检测应纳入临床实践诊断筛查的讨论仍未确定。
- 新技术改变了基因检测的可及性和有效性,需要成本效果分析以支持可持续诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it possible to find the cause of primary ovarian insufficiency (POI) in more women by extensive screening? SUMMARY ANSWER: Adding next generation sequencing techniques including a POI-associated gene panel, extended whole exome sequencing data, as well as specific autoantibody assays to the recommended diagnostic investigations increased the determination of a potential etiological diagnosis of POI from 11% to 41%. WHAT IS KNOWN ALREADY: POI affects ∼1% of women. Clinical presentations and pathogenic mechanisms are heterogeneous and include genetic, autoimmune, and environmental factors, but the underlying etiology remains unknown in the majority of cases. STUDY DESIGN, SIZE, DURATION: Prospective cross-sectional study of 100 women with newly diagnosed POI of unknown cause consecutively referred to Haukeland University Hospital, Bergen, Norway, January 2019 to December 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: In addition to standard recommended diagnostic investigations including screening for chromosomal anomalies and premutations in the fragile X mental retardation 1 gene (FMR1) we used whole exome sequencing, including targeted analysis of 103 ovarian-related genes, and assays of autoantibodies against steroid cell antigens. MAIN RESULTS AND THE ROLE OF CHANCE: We identified chromosomal aberrations in 8%, FMR1 premutations in 3%, genetic variants related to POI in 16%, and autoimmune POI in 3%. Furthermore in 11% we identified POI associated genetic Variants of unknown signifcance (VUS). A homozygous pathogenic variant in the ZSWIM7 gene (NM_001042697.2) was found in two women, corroborating this as a novel cause of monogenic POI. No associations between phenotypes and genotypes were found. LIMITATIONS, REASONS FOR CAUTION: Use of candidate genetic and autoimmune markers limit the possibility to discover new markers. To further investigate the genetic variants, family studies would have been useful. We found a relatively high proportion of genetic variants in women from Africa and lack of genetic diversity in the genomic databases can impact diagnostic accuracy. WIDER IMPLICATIONS OF THE FINDINGS: Since no specific clinical or biochemical markers predicted the underlying cause of POI discussion of which tests should be part of diagnostic screening in clinical practice remains open. New technology has altered the availability and effectiveness of genetic testing, and cost-effectiveness analyses are required to aid sustainable diagnostics. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by grants and fellowships from Stiftelsen Kristian Gerhard Jebsen, the Novonordisk Foundation, the Norwegian Research Council, University of Bergen, and the Regional Health Authorities of Western Norway. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: NCT04082169.
引用
- Vogt EC, Bratland E, Berland S, et al. Improving diagnostic precision in primary ovarian insufficiency using comprehensive genetic and autoantibody testing. Hum Reprod. 2024. PMID: 37953503. doi:10.1093/humrep/dead233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。